AtriCure, Inc. Logo

AtriCure, Inc.

ATRC

(0.5)
Stock Price

30,72 USD

-13.27% ROA

-8.42% ROE

-31.94x PER

Market Cap.

1.330.415.700,00 USD

13.94% DER

0% Yield

-8.7% NPM

AtriCure, Inc. Stock Analysis

AtriCure, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

AtriCure, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (16%), which means it has a small amount of debt compared to the ownership it holds

2 ROE

Negative ROE (-5.4%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (-8.28%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

4 PBV

The stock's high Price-to-Book Value (P/BV) ratio (4.16x) suggests it's overvalued, potentially making it an expensive investment.

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-17), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

AtriCure, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

AtriCure, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

AtriCure, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

AtriCure, Inc. Revenue
Year Revenue Growth
2001 20.000
2002 1.766.000 98.87%
2003 9.792.000 81.96%
2004 19.157.032 48.89%
2005 30.956.987 38.12%
2006 38.243.243 19.05%
2007 48.309.063 20.84%
2008 55.257.023 12.57%
2009 54.533.558 -1.33%
2010 59.006.188 7.58%
2011 64.402.409 8.38%
2012 70.247.000 8.32%
2013 81.889.000 14.22%
2014 107.454.000 23.79%
2015 129.755.000 17.19%
2016 155.109.000 16.35%
2017 174.716.000 11.22%
2018 201.630.000 13.35%
2019 230.807.000 12.64%
2020 206.531.000 -11.75%
2021 274.329.000 24.71%
2022 330.379.000 16.97%
2023 393.160.000 15.97%
2023 399.245.000 1.52%
2024 465.076.000 14.15%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

AtriCure, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2001 0
2002 0 0%
2003 0 0%
2004 4.422.014 100%
2005 9.108.600 51.45%
2006 12.215.617 25.43%
2007 10.987.477 -11.18%
2008 10.608.668 -3.57%
2009 11.414.889 7.06%
2010 11.530.820 1.01%
2011 11.856.821 2.75%
2012 12.147.000 2.39%
2013 13.440.000 9.62%
2014 18.600.000 27.74%
2015 25.742.000 27.74%
2016 35.824.000 28.14%
2017 34.144.000 -4.92%
2018 34.723.000 1.67%
2019 41.230.000 15.78%
2020 43.070.000 4.27%
2021 48.506.000 11.21%
2022 57.337.000 15.4%
2023 81.416.000 29.58%
2023 73.915.000 -10.15%
2024 78.624.000 5.99%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

AtriCure, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2001 0
2002 0 0%
2003 0 0%
2004 15.186.081 100%
2005 24.594.489 38.25%
2006 33.170.328 25.85%
2007 39.752.513 16.56%
2008 42.422.133 6.29%
2009 35.112.006 -20.82%
2010 37.048.715 5.23%
2011 39.870.139 7.08%
2012 45.065.000 11.53%
2013 57.014.000 20.96%
2014 73.510.000 22.44%
2015 93.853.000 21.68%
2016 106.415.000 11.8%
2017 116.998.000 9.05%
2018 129.524.000 9.67%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

AtriCure, Inc. EBITDA
Year EBITDA Growth
2001 -3.140.000
2002 -5.662.000 44.54%
2003 -3.357.000 -68.66%
2004 -4.690.270 28.43%
2005 -9.333.412 49.75%
2006 -12.956.393 27.96%
2007 -10.825.770 -19.68%
2008 -7.933.793 -36.45%
2009 1.927.517 511.61%
2010 -806.298 339.06%
2011 -2.792.458 71.13%
2012 -5.299.000 47.3%
2013 -8.871.000 40.27%
2014 -11.586.000 23.43%
2015 -20.442.000 43.32%
2016 -21.839.000 6.4%
2017 -15.851.000 -37.78%
2018 -8.373.000 -89.31%
2019 -23.756.000 64.75%
2020 -44.233.000 46.29%
2021 -149.795.000 70.47%
2022 -42.669.000 -251.06%
2023 -32.356.000 -31.87%
2023 -16.282.000 -98.72%
2024 -10.564.000 -54.13%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

AtriCure, Inc. Gross Profit
Year Gross Profit Growth
2001 12.000
2002 1.085.000 98.89%
2003 7.180.000 84.89%
2004 13.955.470 48.55%
2005 22.900.307 39.06%
2006 30.616.881 25.2%
2007 38.172.287 19.79%
2008 42.032.519 9.18%
2009 41.782.813 -0.6%
2010 45.387.734 7.94%
2011 46.996.424 3.42%
2012 50.014.000 6.03%
2013 59.563.000 16.03%
2014 75.750.000 21.37%
2015 92.875.000 18.44%
2016 111.101.000 16.4%
2017 126.163.000 11.94%
2018 147.120.000 14.24%
2019 170.335.000 13.63%
2020 149.309.000 -14.08%
2021 205.860.000 27.47%
2022 245.940.000 16.3%
2023 295.476.000 16.76%
2023 297.417.000 0.65%
2024 344.336.000 13.63%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

AtriCure, Inc. Net Profit
Year Net Profit Growth
2001 -3.596.000
2002 -9.031.000 60.18%
2003 -7.108.000 -27.05%
2004 -9.451.868 24.8%
2005 -12.682.964 25.48%
2006 -13.717.275 7.54%
2007 -11.253.066 -21.9%
2008 -10.167.252 -10.68%
2009 -16.494.988 38.36%
2010 -3.791.623 -335.04%
2011 -5.455.503 30.5%
2012 -7.534.000 27.59%
2013 -11.462.000 34.27%
2014 -16.211.000 29.29%
2015 -27.212.000 40.43%
2016 -33.338.000 18.38%
2017 -26.892.000 -23.97%
2018 -21.137.000 -27.23%
2019 -35.194.000 39.94%
2020 -48.155.000 26.92%
2021 50.199.000 195.93%
2022 -46.466.000 208.03%
2023 -36.220.000 -28.29%
2023 -30.438.000 -19%
2024 -32.031.996 4.98%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

AtriCure, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2001 -2
2002 -5 60%
2003 -4 -66.67%
2004 -5 40%
2005 -2 -150%
2006 -1 -100%
2007 -1 0%
2008 -1 0%
2009 -1 100%
2010 0 0%
2011 0 0%
2012 0 0%
2013 -1 0%
2014 -1 0%
2015 -1 0%
2016 -1 100%
2017 -1 0%
2018 -1 0%
2019 -1 0%
2020 -1 100%
2021 1 200%
2022 -1 200%
2023 -1 0%
2023 -1 0%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

AtriCure, Inc. Free Cashflow
Year Free Cashflow Growth
2004 -5.313.344
2005 -9.567.642 44.47%
2006 -14.146.250 32.37%
2007 -11.160.174 -26.76%
2008 -7.457.530 -49.65%
2009 -940.511 -692.92%
2010 -1.847.246 49.09%
2011 -3.508.737 47.35%
2012 -4.921.000 28.7%
2013 -8.086.000 39.14%
2014 -30.807.000 73.75%
2015 -31.839.000 3.24%
2016 -22.811.000 -39.58%
2017 -15.328.000 -48.82%
2018 -10.382.000 -47.64%
2019 -27.993.000 62.91%
2020 -25.128.000 -11.4%
2021 -23.533.000 -6.78%
2022 -39.022.000 39.69%
2023 -37.574.000 -3.85%
2023 0 0%
2024 5.856.000 100%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

AtriCure, Inc. Operating Cashflow
Year Operating Cashflow Growth
2004 -3.800.071
2005 -7.615.909 50.1%
2006 -12.465.730 38.91%
2007 -8.115.628 -53.6%
2008 -5.709.940 -42.13%
2009 419.948 1459.68%
2010 -33.434 1356.05%
2011 -1.986.426 98.32%
2012 -1.936.000 -2.6%
2013 -5.222.000 62.93%
2014 -21.600.000 75.82%
2015 -7.842.000 -175.44%
2016 -15.119.000 48.13%
2017 -8.944.000 -69.04%
2018 -4.171.000 -114.43%
2019 -15.811.000 73.62%
2020 -19.869.000 20.42%
2021 -13.780.000 -44.19%
2022 -22.141.000 37.76%
2023 4.424.000 600.47%
2023 0 0%
2024 8.240.000 100%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

AtriCure, Inc. Capital Expenditure
Year Capital Expenditure Growth
2004 1.513.273
2005 1.951.733 22.47%
2006 1.680.520 -16.14%
2007 3.044.546 44.8%
2008 1.747.590 -74.21%
2009 1.360.459 -28.46%
2010 1.813.812 24.99%
2011 1.522.311 -19.15%
2012 2.985.000 49%
2013 2.864.000 -4.22%
2014 9.207.000 68.89%
2015 23.997.000 61.63%
2016 7.692.000 -211.97%
2017 6.384.000 -20.49%
2018 6.211.000 -2.79%
2019 12.182.000 49.01%
2020 5.259.000 -131.64%
2021 9.753.000 46.08%
2022 16.881.000 42.22%
2023 41.998.000 59.81%
2023 0 0%
2024 2.384.000 100%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

AtriCure, Inc. Equity
Year Equity Growth
2001 1.731.000
2002 17.020.000 89.83%
2003 -18.937.000 189.88%
2004 -27.331.294 30.71%
2005 43.183.452 163.29%
2006 30.694.262 -40.69%
2007 36.236.502 15.29%
2008 29.119.157 -24.44%
2009 17.089.760 -70.39%
2010 16.735.930 -2.11%
2011 15.614.704 -7.18%
2012 12.500.000 -24.92%
2013 72.604.000 82.78%
2014 132.538.000 45.22%
2015 186.685.000 29%
2016 168.442.000 -10.83%
2017 161.166.000 -4.51%
2018 249.381.000 35.37%
2019 247.343.000 -0.82%
2020 412.394.000 40.02%
2021 483.756.000 14.75%
2022 456.754.000 -5.91%
2023 466.168.000 2.02%
2023 462.833.000 -0.72%
2024 462.085.000 -0.16%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

AtriCure, Inc. Assets
Year Assets Growth
2001 2.051.000
2002 17.586.000 88.34%
2003 14.759.000 -19.15%
2004 12.730.620 -15.93%
2005 50.040.415 74.56%
2006 39.128.065 -27.89%
2007 46.071.496 15.07%
2008 43.368.832 -6.23%
2009 34.982.336 -23.97%
2010 33.715.714 -3.76%
2011 33.858.890 0.42%
2012 32.431.000 -4.4%
2013 111.947.000 71.03%
2014 158.404.000 29.33%
2015 273.092.000 42%
2016 276.421.000 1.2%
2017 267.704.000 -3.26%
2018 356.759.000 24.96%
2019 557.880.000 36.05%
2020 714.539.000 21.92%
2021 615.312.000 -16.13%
2022 585.448.000 -5.1%
2023 613.932.000 4.64%
2023 600.271.000 -2.28%
2024 597.273.000 -0.5%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

AtriCure, Inc. Liabilities
Year Liabilities Growth
2001 320.000
2002 566.000 43.46%
2003 33.696.000 98.32%
2004 40.061.914 15.89%
2005 6.856.963 -484.25%
2006 8.433.803 18.7%
2007 9.834.994 14.25%
2008 14.249.675 30.98%
2009 17.892.576 20.36%
2010 16.979.784 -5.38%
2011 18.244.186 6.93%
2012 19.931.000 8.46%
2013 39.343.000 49.34%
2014 25.866.000 -52.1%
2015 86.407.000 70.06%
2016 107.979.000 19.98%
2017 106.538.000 -1.35%
2018 107.378.000 0.78%
2019 310.537.000 65.42%
2020 302.145.000 -2.78%
2021 131.556.000 -129.67%
2022 128.694.000 -2.22%
2023 147.764.000 12.91%
2023 137.438.000 -7.51%
2024 135.188.000 -1.66%

AtriCure, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
9.17
Net Income per Share
-0.86
Price to Earning Ratio
-31.94x
Price To Sales Ratio
3.09x
POCF Ratio
-158.53
PFCF Ratio
-67.68
Price to Book Ratio
2.77
EV to Sales
3.02
EV Over EBITDA
-59.94
EV to Operating CashFlow
-160.77
EV to FreeCashFlow
-66.12
Earnings Yield
-0.03
FreeCashFlow Yield
-0.01
Market Cap
1,33 Bil.
Enterprise Value
1,30 Bil.
Graham Number
13.77
Graham NetNet
1.22

Income Statement Metrics

Net Income per Share
-0.86
Income Quality
0.2
ROE
-0.09
Return On Assets
-0.06
Return On Capital Employed
-0.06
Net Income per EBT
1.03
EBT Per Ebit
1.11
Ebit per Revenue
-0.08
Effective Tax Rate
-0.03

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.19
Stock Based Compensation to Revenue
0.09
Gross Profit Margin
0.74
Operating Profit Margin
-0.08
Pretax Profit Margin
-0.08
Net Profit Margin
-0.09

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.17
Free CashFlow per Share
-0.42
Capex to Operating CashFlow
-1.43
Capex to Revenue
0.03
Capex to Depreciation
0.67
Return on Invested Capital
-0.07
Return on Tangible Assets
-0.13
Days Sales Outstanding
47.17
Days Payables Outstanding
88.17
Days of Inventory on Hand
243.53
Receivables Turnover
7.74
Payables Turnover
4.14
Inventory Turnover
1.5
Capex per Share
0.25

Balance Sheet

Cash per Share
2,43
Book Value per Share
9,85
Tangible Book Value per Share
3.56
Shareholders Equity per Share
9.85
Interest Debt per Share
1.44
Debt to Equity
0.14
Debt to Assets
0.11
Net Debt to EBITDA
1.42
Current Ratio
4.13
Tangible Asset Value
0,17 Bil.
Net Current Asset Value
0,12 Bil.
Invested Capital
532851000
Working Capital
0,19 Bil.
Intangibles to Total Assets
0.49
Average Receivables
0,06 Bil.
Average Payables
0,03 Bil.
Average Inventory
72799500
Debt to Market Cap
0.05

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

AtriCure, Inc. Dividends
Year Dividends Growth

AtriCure, Inc. Profile

About AtriCure, Inc.

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

CEO
Mr. Michael H. Carrel
Employee
1.200
Address
7555 Innovation Way
Mason, 45040

AtriCure, Inc. Executives & BODs

AtriCure, Inc. Executives & BODs
# Name Age
1 Mr. Douglas J. Seith
Chief Operating Officer
70
2 Valerie Storch-Willhaus
Vice President of Corporate Marketing & Communications
70
3 Mr. Michael H. Carrel
Chief Executive Officer, President & Director
70
4 Mr. Karl S. Dahlquist CCEP, J.D.
Chief Legal Officer
70
5 Dr. Vinayak Doraiswamy Ph.D.
Chief Scientific Officer
70
6 Mr. Justin J. Noznesky
Chief Marketing & Strategy Officer
70
7 Ms. Deborah Yount
Chief Human Resources Officer
70
8 Ms. Angela L. Wirick CPA
Chief Financial Officer
70
9 Mr. Salvatore Privitera J.D.
Chief Technical Officer
70

AtriCure, Inc. Competitors

AngioDynamics, Inc. Logo
AngioDynamics, Inc.

ANGO

(1.5)
Atrion Corporation Logo
Atrion Corporation

ATRI

(2.8)
CONMED Corporation Logo
CONMED Corporation

CNMD

(1.5)
AxoGen, Inc. Logo
AxoGen, Inc.

AXGN

(1.2)